Patents by Inventor Steven Jacobs

Steven Jacobs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12202732
    Abstract: An aqueous hydrophobic silica dispersion includes a hydrophilic particulate silica, a hydrophobic particulate silica having a methanol number of at least 60, and a dispersant having at least one cationic or cationizable group and an HLB ratio of 2 to 20.
    Type: Grant
    Filed: April 17, 2024
    Date of Patent: January 21, 2025
    Assignee: Cabot Corporation
    Inventors: Lang H. Nguyen, Kavita K. Pai, Steven Jacobs, Tianqi Liu, Melissa J. Monello, Angelica M. Sanchez Garcia, Zhangliang Gui, Takashi Umehara
  • Publication number: 20240301033
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: February 8, 2024
    Publication date: September 12, 2024
    Inventors: Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20240262699
    Abstract: An aqueous hydrophobic silica dispersion includes a hydrophilic particulate silica, a hydrophobic particulate silica having a methanol number of at least 60, and a dispersant having at least one cationic or cationizable group and an HLB ratio of 2 to 20.
    Type: Application
    Filed: April 17, 2024
    Publication date: August 8, 2024
    Inventors: Lang H. Nguyen, Kavita K. Pai, Steven Jacobs, Tianqi Liu, Melissa J. Monello, Angelica M. Sanchez Garcia, Zhangliang Gui, Takashi Umehara
  • Patent number: 12054534
    Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: August 6, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rosa Cardoso, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Donna Klein, Karyn O'Neil, Tracy Spinka-Doms
  • Patent number: 11987501
    Abstract: An aqueous hydrophobic silica dispersion includes a hydrophilic particulate silica, a hydrophobic particulate silica having a methanol number of at least 60, and a dispersant having at least one cationic or cationizable group and an HLB ratio of 2 to 20.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 21, 2024
    Assignee: Cabot Corporation
    Inventors: Lang H. Nguyen, Kavita K. Pai, Steven Jacobs, Tianqi Liu, Melissa J. Monello, Angelica M. Sanchez Garcia, Zhangliang Gui, Takashi Umehara
  • Publication number: 20240100129
    Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
    Type: Application
    Filed: October 27, 2023
    Publication date: March 28, 2024
    Inventors: Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
  • Patent number: 11932680
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: March 19, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 11833190
    Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: December 5, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
  • Patent number: 11702475
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: July 18, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Shalom Goldberg, Steven Jacobs, Tricia Lin, Karyn O'Neil
  • Publication number: 20230181415
    Abstract: A method and device that provides an improved way to treat lymphedema. An ultrasonic fluid pump including speakers attached to a flexible material stocking, combined with a controller, which is adapted to control the operation of the speakers to enable the speakers to cause fluid to flow in a predetermined direction.
    Type: Application
    Filed: December 13, 2022
    Publication date: June 15, 2023
    Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Steven Jacob Mahaffey, Paul Krautter
  • Publication number: 20230143550
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: March 8, 2022
    Publication date: May 11, 2023
    Inventors: Rebecca HAWKINS, Steven JACOBS, Manuel SEPULVEDA
  • Publication number: 20230071749
    Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.
    Type: Application
    Filed: September 14, 2022
    Publication date: March 9, 2023
    Inventors: Steven Jacobs, Karyn O'Neil
  • Publication number: 20220411504
    Abstract: The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3?, polynucleotides encoding them, vectors, host cells, methods of making and using them.
    Type: Application
    Filed: May 26, 2021
    Publication date: December 29, 2022
    Inventors: Raymond Brittingham, Scott R. Brodeur, Rajkumar Ganesan, Jaclyn Hoover, Steven A. Jacobs, Colleen M. Kane, Jinquan Luo, Sanjaya Singh, Fang Yi, Adam Zwolak, Triveni K. Bhatt, Michael Dennis Feldkamp, Sherry Lynn La Porte
  • Publication number: 20220344902
    Abstract: A semiconductor laser including a waveguide having a core, a confinement layer to bury the core, and a metallization layer. The core includes an active core region. The confinement layer surrounds the core and includes a first confinement layer between the core and the semiconductor substrate below the core, a second confinement layer above the core, and a third confinement layer to either or both sides of the core. The metallization layer is located above the confinement layers and include a first metallization layer and a second metallization layer. The first metallization layer is in direct contact with the second confinement layer and the third confinement layer, while the second metallization layer is disposed above the first layer. The first metallization layer is tuned to have a plasmon resonance corresponding to a higher order mode with high loss.
    Type: Application
    Filed: April 22, 2022
    Publication date: October 27, 2022
    Inventors: Steven A. Jacobs, Robert A. Marsland
  • Patent number: 11479880
    Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: October 25, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Steven Jacobs, Karyn O'Neil
  • Patent number: 11447539
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: September 20, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Publication number: 20220259289
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 18, 2022
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 11345739
    Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: May 31, 2022
    Assignee: JANSSEN BIOTECH, INC
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 11299534
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: April 12, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: D1034811
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: July 9, 2024
    Assignee: The Pokémon Company International, Inc.
    Inventors: Stefan Alano, Louis Hsiao, Steven Jacobs, Emily Schooley, Alex Doumani, Philip Shen